The European Commission has just granted Orphan drug status to the BL-8040 (Motixafortide) pancreatic cancer treatment from Israel’s BioLineRX (see here). BioLineRX can now receive benefits including EU funding, less regulation, and market exclusivity.
Orphan status for pancreatic cancer treatment
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.